If approved, the neonatal Fc receptor blocker would become the first FDA-authorized therapy specifically indicated for patients with wAIHA.

Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) for IMAAVY® (nipocalimab-aahu),c ...

Priority Review is granted to medicines that may offer significant improvements in safety or effectiveness for serious conditions like warm autoimmune hemolytic anemia ...

Two papers published in The New England Journal of Medicine highlight the potential of gene editing for treatment of sickle ...

Sanofi Q1 2026 earnings preview: revenue growth, discounted 9.66x forward P/E, and Dupixent EC approval—see why SNY stock ...

A 47-year-old woman in Germany had spent more than a decade battling three severe autoimmune diseases at once: autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), and antiphospholipid ...

Through 120 weeks of follow-up, IMAAVY delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ ...

Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, today announced the first patient has been dosed in multiple Phase II studies of ...

A woman in her thirties who was dependent on blood transfusions and unresponsive to every standard treatment for her three ...

Older adults with anemia had 66% higher odds of developing dementia, with those with elevated Alzheimer’s disease blood ...

Anemia is common in patients with autoimmune gastritis and is associated with positivity for anti-intrinsic factor antibodies.

A groundbreaking new study introduces an AI-powered smartphone app that noninvasively screens for anemia using a photo of a user's fingernail. The study shows the app provides hemoglobin estimates ...